The successful use of a Bruton tyrosine kinase (BTK) inhibitor to target the BCR pathway in DLBCL has yielded profound discoveries regarding the genetic and biochemical basis of BCR signaling. This evidence concerns the gene BCR and diffuse large B-cell lymphoma.